COVID Vaccines Show Promise in Boosting Cancer Immunotherapy, Study Finds
GAINESVILLE, FL – In a potentially groundbreaking discovery, a new study reveals that patients receiving Pfizer or Moderna’s mRNA-based COVID-19 vaccines shortly before or during immunotherapy treatment experienced substantially improved survival rates, even with cancers previously unresponsive to such therapies. Researchers at the University of Florida suggest the vaccines act as an “alarm,” awakening the immune system to recognize adn attack tumor cells.
the research, led by pediatric oncologist elias Sayour, found that patients vaccinated within 100 days of starting immunotherapy where twice as likely to be alive after three years compared to unvaccinated patients. Remarkably, those with “cold” tumors – cancers known to evade immune detection – saw nearly a five-fold improvement in three-year overall survival. This positive correlation held even after accounting for disease severity and other health conditions.
“mRNA vaccines that are not specific to a patient’s cancer can ‘awaken the sleeping giant that is the immune system to fight cancer,'” explained Sayour.
Using animal models, the team discovered that the COVID-19 mRNA vaccines trigger a systemic immune response that overcomes cancer’s ability to suppress immune cells. This allows immunotherapy, specifically immune checkpoint inhibitors, to function more effectively.Immune checkpoint inhibitors have revolutionized cancer treatment in the last decade, offering cures for previously incurable patients, but are often ineffective against “cold” tumors.
The study,published in part with supporting data available at https://doi.org/10.1016/j.cell.2023.03.006, suggests a novel approach to enhancing cancer treatment by leveraging the power of broadly acting mRNA vaccines. Further research, including work detailed by researcher https://scholar.google.com/citations?user=E2q2tK8AAAAJ&hl=en, is underway to fully understand the mechanisms at play and explore potential clinical applications.
